P
Paula M. Martikainen
Researcher at University of Tampere
Publications - 37
Citations - 1567
Paula M. Martikainen is an academic researcher from University of Tampere. The author has contributed to research in topics: Prostate cancer & Prostate cancer screening. The author has an hindex of 20, co-authored 37 publications receiving 1500 citations. Previous affiliations of Paula M. Martikainen include Tampere University of Technology.
Papers
More filters
Journal ArticleDOI
TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis
Outi R. Saramäki,Anna E. Harjula,Paula M. Martikainen,Robert L. Vessella,Teuvo L.J. Tammela,Tapio Visakorpi +5 more
TL;DR: The TMPRSS2:ERG rearrangement can be found in about one third of prostate cancers and is associated with longer progression-free survival in patients treated by prostatectomy, and was an independent predictor of favorable outcome.
Book ChapterDOI
Antiproliferative action of vitamin D.
Timo Ylikomi,Ilkka Laaksi,Yan-Ru Lou,Paula M. Martikainen,Susanna Miettinen,Pasi Pennanen,Sami Purmonen,Heimo Syvälä,Annika Vienonen,Pentti Tuohimaa +9 more
TL;DR: The mechanisms whereby vitamin D regulates cell proliferation are discussed and whether it could be used in prevention and treatment of hyperproliferative disorders like cancers like cancers are discussed.
Journal ArticleDOI
The Gene for Polycomb Group Protein Enhancer of Zeste Homolog 2 (EZH2) is Amplified in Late-Stage Prostate Cancer
TL;DR: The data show that amplification of the EZH2 gene is rare in early prostate cancer, whereas a fraction of late‐stage tumors contains the gene amplification leading to the overexpression of the gene, thus indicating the importance of EZh2 in the progression of prostate cancer.
Journal ArticleDOI
Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype
TL;DR: The results show that expression of claudins 1, 3, 4 and 5 is lower in diffuse-type gastric carcinomas, possibly they play a role in determining the diffuse phenotype and loose cohesion of cells in diffuse type of Gastric carcinoma in a similar manner as E-cadherin.
Journal ArticleDOI
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
Sari Laitinen,Paula M. Martikainen,Teemu Tolonen,Jorma Isola,Teuvo L.J. Tammela,Tapio Visakorpi +5 more
TL;DR: Ki‐67, EZH2 and MCM7 are potential prognostic biomarkers in prostatectomy treated patients and showed independent prognostic value with relative risks in multivariate analysis.